| 11.06 09:50 | dpa-AFX: *CITIGROUP RAISES HIKMA PHARMACEUTICAL PRICE TARGET TO 2845 (2770) PENCE - 'BUY' |
| 03.05 08:44 | dpa-AFX: *DEUTSCHE BANK INITIATES HIKMA PHARMACEUTICAL WITH 'BUY' - TARGET 2750 PENCE |
| 25.04 09:08 | dpa-AFX: Hikma Pharma Projects 2024 Group Revenue To Grow In Range Of 4% - 6% |
| 25.04 08:28 | dpa-AFX: *HIKMA PHARMA EXPECTS 2024 GROUP REVENUE TO GROW IN RANGE OF 4% TO 6% |
| 25.04 08:21 | dpa-AFX: *HIKMA PHARMA TO PAY FINAL DIVIDEND OF 47 CENTS PER SHARE |
| 25.04 08:20 | dpa-AFX: *HIKMA PHARMA STILL EXPECTS FY CORE OPERATING PROFIT TO BE $660 MLN TO $700 MLN |
| 25.04 08:20 | dpa-AFX: *HIKMA PHARMA STILL EXPECTS FY REVENUE GROWTH TO BE 4% TO 6% |
| 29.02 07:45 | dpa-AFX: *RBC RAISES HIKMA PHARMA PRICE TARGET TO 2375 (2175) PENCE - 'SECTOR PERFORM' |
| 27.02 10:33 | dpa-AFX: *BERENBERG RAISES HIKMA PHARMACEUTICAL TARGET TO 2000 (1960) PENCE - 'HOLD' |
| 23.02 07:11 | dpa-AFX: *BARCLAYS RAISES HIKMA PHARMACEUTICAL TARGET TO 2000 (1850) P. - 'EQUAL WEIGHT' |
| 22.02 09:28 | dpa-AFX: Hikma Pharma FY Profit Increases |
| 22.02 08:40 | dpa-AFX: *JPMORGAN RAISES HIKMA PHARMACEUTICAL PT TO 2350 (2200) PENCE - 'OVERWEIGHT' |
| 22.02 08:23 | dpa-AFX: *HIKMA PHARMA FY CORE BASIC EPS 223C VS 181C LAST YEAR |
| 22.02 08:08 | dpa-AFX: *HIKMA PHARMACEUTICALS FY23 CORE PROFIT $492 MLN VS. $406 MLN LAST YEAR |
| 22.02 08:08 | dpa-AFX: *HIKMA PHARMACEUTICALS FY23 PROFIT ATTRIBUTABLE TO SHAREHOLDERS $190 MLN VS. $188 MLN LAST YEAR |
| 22.02 08:07 | dpa-AFX: *HIKMA PHARMACEUTICALS FY23 REVENUE $2.875 BLN VS. $2.517 BLN LAST YEAR |
| 05.02 13:30 | dpa-AFX: Hikma Pharma Launches Pain Relief Injection COMBOGESIC IV In US |
| 05.02 13:03 | dpa-AFX: *HIKMA ANNOUNCES LAUNCH OF COMBOGESIC IV INJECTION IN THE US |
| 09.01 07:12 | dpa-AFX: *RBC RAISES HIKMA PHARMA PRICE TARGET TO 2175 (2150) PENCE - 'SECTOR PERFORM' |
| 08.01 08:58 | dpa-AFX: Guardant Health, Hikma To Offer Cancer Screening & Genomic Profiling Tests In Middle East & Africa |
|
|
